Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 7/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TPMT | P51580 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5909057 | 0.89 | CA12 (0.58) | CA12CA9MEN1LMNAMAPT | |
| Chlorobenzene SCHEMBL28001559 | 0.87 | LMNA (0.52) | FOLH1MEN1LMNAMAPTHPGD | |
| SCHEMBL17553165 | 0.84 | KDM4E (0.60) | FOLH1CYP1A2CYP2D6CYP2C9KMT2A | |
| SCHEMBL9475078 | 0.83 | CYP1A2 (0.51) | FOLH1CYP1A2CYP2D6CYP2C9LMNA | |
| SCHEMBL13382304 | 0.82 | HPGDS (0.48) | MEN1KMT2AHDAC4HDAC6ALDH1A1 | |
| SCHEMBL18782285 | 0.81 | L3MBTL1 (0.63) | FOLH1CA2ALDH1A1 | |
| SCHEMBL12347956 | 0.81 | EPHX2 (0.54) | CA12CA9MEN1LMNAMAPT | |
| SCHEMBL8158111 | 0.81 | NR1H4 (0.54) | CA12CA9CYP1A2MEN1LMNA | |
| SCHEMBL13702393 | 0.81 | PLK1 (0.66) | CA12CA9MEN1LMNAMAPT | |
| SCHEMBL92285 | 0.81 | GFER (0.59) | CA12CA9CYP1A2CYP2D6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233726-A1 | Method for Making an Enriched Library | VIPERGEN APS (DK) | 2017-08-17 | — | — | US | disclosed |
| WO-2016138135-A1 | SIGMA-1 RECEPTOR MODULATORS FOR TREATING HUNTINGTON'S DISEASE | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2016-09-01 | — | — | WO | disclosed |
| CN-105408332-A | Substituted triazolopyridines | Bayer Pharma AG | 2016-03-16 | — | — | CN | disclosed |
| US-20130288929-A1 | Method for Making an Enriched Library | VIPERGEN (DK) | 2013-10-31 | — | — | US | disclosed |
| WO-2011088405-A1 | PLASMA MODIFICATION OF METAL SURFACES | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2011-07-21 | — | — | WO | disclosed |
| EP-2073850-B1 | HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS | INTEZYNE TECHNOLOGIES INC (US) | 2010-10-27 | — | — | EP | disclosed |
| US-20100098633-A1 | SELECTIVE SEPRASE INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-04-22 | — | — | US | disclosed |
| EP-1907444-B1 | POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES INC (US) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008134734-A2 | ENCAPSULATED CONTRAST AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008106657-A2 | ENCAPSULATED AMYLOID-BETA PEPTIDES | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| US-6368608-B1 | SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHE DERMATOLOGIQUES GALDERMA (C.I.R.D.) (FR) | 2002-04-09 | — | — | US | disclosed |
| US-6162445-A | Polyaromatic propynyl compounds and pharmaceutical/cosmetic compositions comprised thereof | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-12-19 | — | — | US | disclosed |
| EP-0661258-B1 | Biaromatic propynyl compounds, pharmaceutical compositions and cosmetics containing them and their uses | CIRD GALDERMA (FR) | 1998-04-08 | — | — | EP | disclosed |
| US-5716624-A | USEFUL FOR TREATING DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR, OPTHALMOLOGICAL DISORDERS, AS WELL AS MAMMALIAN SKIN AND HAIR CONDITIONS/DISORDERS | C.I.R.D. GALDERMA (FR) | 1998-02-10 | — | — | US | disclosed |
| EP-0661258-A1 | Biaromatic propynyl compounds, pharmaceutical compositions and cosmetics containing them and their uses | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100098633-A1 | SELECTIVE SEPRASE INHIBITORS | SLC6A7, DNPEP, PREP | FOLH1 41/4885CA12 2126/4885CA9 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.